{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:40:31Z","timestamp":1784367631338,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fonds der Stadt Wien f\u00fcr innovative interdisziplin\u00e4re Krebsforschung"},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["T 1062-B33"],"award-info":[{"award-number":["T 1062-B33"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The cold-shock domain protein YB-1 is overexpressed in pleural mesothelioma (PM) and was shown to contribute to increased cell migration and platinum resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phosphorylation of YB-1 at position serine 102 was analysed by immunohistochemistry, immunofluorescence and immunoblotting in PM tissue specimens and cell lines. Intracellular localisation experiments involved immunoblotting, transfection of fluorescent protein-tagged YB-1 and confocal imaging. YB-1 phosphorylation was inhibited with the RSK inhibitors BI-D1870 and LJH685. Effects of inhibition alone and in combination with radiation or cisplatin treatment were analysed by cell viability assays, clonogenic assays and videomicroscopy-based migration and cell fate map analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>YB-1 phosphorylated at serine 102 is present in PM cell lines and tissue. Inhibition of phosphorylation with BI-D1870 reduced YB-1 localisation in the cell nucleus and led to reduced cell viability, clonogenicity, migration and disrupted cell division. Moreover, exposure to BI-D1870 increased the effect of radiation and cisplatin treatment with additive to synergistic effects in PM cell lines and primary cultures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The serine 102 phosphorylated form of YB-1 contributes to the malignant phenotype of PM. Inhibition of YB-1 phosphorylation warrants further exploration as part of treatment strategies for this devastating disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03177-0","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:28:04Z","timestamp":1756985284000},"page":"1391-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-1737","authenticated-orcid":false,"given":"Karin","family":"Schelch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Maach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Zitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Kirchhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Timelthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Solta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Emminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-1398","authenticated-orcid":false,"given":"Verena","family":"Kopatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir A.","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-1658","authenticated-orcid":false,"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-991X","authenticated-orcid":false,"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8624","authenticated-orcid":false,"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9340","authenticated-orcid":false,"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"3177_CR1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/1878-0261.13591","volume":"18","author":"M Rigon","year":"2024","unstructured":"Rigon M, Mutti L, Campanella M. Pleural mesothelioma (PMe): the evolving molecular knowledge of a rare and aggressive cancer. Mol Oncol. 2024;18:797\u2013814.","journal-title":"Mol Oncol"},{"key":"3177_CR2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","volume":"13","author":"L Mutti","year":"2018","unstructured":"Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, et al. Scientific advances and new frontiers in mesothelioma therapeutics. J Thorac Oncol. 2018;13:1269\u201383.","journal-title":"J Thorac Oncol"},{"key":"3177_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"3177_CR4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207\u201318.","journal-title":"N Engl J Med"},{"key":"3177_CR5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","volume":"19","author":"N McNamee","year":"2024","unstructured":"McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, et al. Brief report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso. J Thorac Oncol. 2024;19:636\u201342.","journal-title":"J Thorac Oncol"},{"key":"3177_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fcell.2019.00221","volume":"7","author":"TG Johnson","year":"2019","unstructured":"Johnson TG, Schelch K, Mehta S, Burgess A, Reid G. Why be one protein when you can affect many? The multiple roles of YB-1 in lung cancer and mesothelioma. Front Cell Dev Biol. 2019;7:221.","journal-title":"Front Cell Dev Biol"},{"key":"3177_CR7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2017.10.016","volume":"13","author":"TG Johnson","year":"2018","unstructured":"Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, et al. Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma. J Thorac Oncol. 2018;13:258\u201372.","journal-title":"J Thorac Oncol"},{"key":"3177_CR8","doi-asserted-by":"crossref","unstructured":"Johnson TG, Schelch K, Lai K, Marzec KA, Kennerson M, Grusch M, et al. YB-1 knockdown inhibits the proliferation of mesothelioma cells through multiple mechanisms. Cancers. 2020;12:2285.","DOI":"10.3390\/cancers12082285"},{"key":"3177_CR9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216395","volume":"574","author":"K Schelch","year":"2023","unstructured":"Schelch K, Emminger D, Zitta B, Johnson TG, Kopatz V, Eder S, et al. Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo. Cancer Lett. 2023;574:216395.","journal-title":"Cancer Lett"},{"key":"3177_CR10","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/stem.1128","volume":"30","author":"AL Stratford","year":"2012","unstructured":"Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, et al. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells. 2012;30:1338\u201348.","journal-title":"Stem Cells"},{"key":"3177_CR11","doi-asserted-by":"crossref","unstructured":"Mehta S, Algie M, Al-Jabry T, McKinney C, Kannan S, Verma CS, et al. Critical role for cold shock protein YB-1 in cytokinesis. Cancers. 2020;12:2473.","DOI":"10.3390\/cancers12092473"},{"key":"3177_CR12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/cdd.2016.141","volume":"24","author":"S Gieseler-Halbach","year":"2017","unstructured":"Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, et al. RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death Differ. 2017;24:371\u201383.","journal-title":"Cell Death Differ"},{"key":"3177_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.yexcr.2016.07.003","volume":"346","author":"X Miao","year":"2016","unstructured":"Miao X, Wu Y, Wang Y, Zhu X, Yin H, He Y, et al. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp Cell Res. 2016;346:157\u201366.","journal-title":"Exp Cell Res"},{"key":"3177_CR14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1541-7786.MCR-17-0528","volume":"16","author":"C Kosnopfel","year":"2018","unstructured":"Kosnopfel C, Sinnberg T, Sauer B, Busch C, Niessner H, Schmitt A, et al. YB-1 expression and phosphorylation regulate tumorigenicity and invasiveness in melanoma by influencing EMT. Mol Cancer Res. 2018;16:1149\u201360.","journal-title":"Mol Cancer Res"},{"key":"3177_CR15","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","volume":"26","author":"C Pirker","year":"2020","unstructured":"Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. Clin Cancer Res. 2020;26:3819\u201330.","journal-title":"Clin Cancer Res"},{"key":"3177_CR16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","volume":"190","author":"K Schelch","year":"2014","unstructured":"Schelch K, Hoda MA, Klikovits T, Munzker J, Ghanim B, Wagner C, et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am J Respir Crit Care Med. 2014;190:763\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"3177_CR17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/carcin\/bgy018","volume":"39","author":"K Schelch","year":"2018","unstructured":"Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal. Carcinogenesis. 2018;39:534\u201345.","journal-title":"Carcinogenesis"},{"key":"3177_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2009.321","volume":"29","author":"SB Cohen","year":"2010","unstructured":"Cohen SB, Ma W, Valova VA, Algie M, Harfoot R, Woolley AG, et al. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene. 2010;29:403\u201310.","journal-title":"Oncogene"},{"key":"3177_CR19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","volume":"12","author":"K Schelch","year":"2018","unstructured":"Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, et al. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. Mol Oncol. 2018;12:58\u201373.","journal-title":"Mol Oncol"},{"key":"3177_CR20","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866\u20138.","journal-title":"Bioinformatics"},{"key":"3177_CR21","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.634371","volume":"9","author":"K Schelch","year":"2021","unstructured":"Schelch K, Vogel L, Schneller A, Brankovic J, Mohr T, Mayer RL, et al. EGF induces migration independent of EMT or invasion in A549 lung adenocarcinoma cells. Front Cell Dev Biol. 2021;9:634371.","journal-title":"Front Cell Dev Biol"},{"key":"3177_CR22","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/nprot.2014.131","volume":"9","author":"R Gorelik","year":"2014","unstructured":"Gorelik R, Gautreau A. Quantitative and unbiased analysis of directional persistence in cell migration. Nat Protoc. 2014;9:1931\u201343.","journal-title":"Nat Protoc"},{"key":"3177_CR23","volume":"299","author":"J Lopez","year":"2023","unstructured":"Lopez J, Bonsor DA, Sale MJ, Urisman A, Mehalko JL, Cabanski-Dunning M, et al. The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling. J Biol Chem. 2023;299:104789.","journal-title":"J Biol Chem"},{"key":"3177_CR24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/1878-0261.13367","volume":"18","author":"K Schelch","year":"2024","unstructured":"Schelch K, Eder S, Zitta B, Phimmachanh M, Johnson TG, Emminger D, et al. YB-1 regulates mesothelioma cell migration via snail but not EGFR, MMP1, EPHA5 or PARK2. Mol Oncol. 2024;18:815\u201331.","journal-title":"Mol Oncol"},{"key":"3177_CR25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1541-7786.MCR-13-0595","volume":"12","author":"I Aronchik","year":"2014","unstructured":"Aronchik I, Appleton BA, Basham SE, Crawford K, Del Rosario M, Doyle LV, et al. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. Mol Cancer Res. 2014;12:803\u201312.","journal-title":"Mol Cancer Res"},{"key":"3177_CR26","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1349-7006.2011.01948.x","volume":"102","author":"C Garand","year":"2011","unstructured":"Garand C, Guay D, Sereduk C, Chow D, Tsofack SP, Langlois M, et al. An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells. Cancer Sci. 2011;102:1410\u20137.","journal-title":"Cancer Sci"},{"key":"3177_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109867","volume":"188","author":"S Khozooei","year":"2023","unstructured":"Khozooei S, Veerappan S, Bonzheim I, Singer S, Gani C, Toulany M. Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaks. Radiother Oncol. 2023;188:109867.","journal-title":"Radiother Oncol"},{"key":"3177_CR28","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/sj.onc.1208590","volume":"24","author":"BW Sutherland","year":"2005","unstructured":"Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24:4281\u201392.","journal-title":"Oncogene"},{"key":"3177_CR29","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep. 2009;2:181\u20138.","journal-title":"Mol Med Rep"},{"key":"3177_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110073","volume":"85","author":"A Alkrekshi","year":"2021","unstructured":"Alkrekshi A, Wang W, Rana PS, Markovic V, Sossey-Alaoui K. A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Cell Signal. 2021;85:110073.","journal-title":"Cell Signal"},{"key":"3177_CR31","doi-asserted-by":"crossref","unstructured":"Yang JW, Sun C, Jin QY, Qiao XH, Guo XL. Potential therapeutic strategies for targeting Y-box-binding protein 1 in cancers. Curr Cancer Drug Targets. 2021;21:897\u2013906.","DOI":"10.2174\/1568009621666210831125001"},{"key":"3177_CR32","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386\u201396.","journal-title":"Lancet Oncol"},{"key":"3177_CR33","volume":"20","author":"AM El-Naggar","year":"2019","unstructured":"El-Naggar AM, Somasekharan SP, Wang Y, Cheng H, Negri GL, Pan M, et al. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep. 2019;20:e48375.","journal-title":"EMBO Rep"},{"key":"3177_CR34","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-23-1795","volume":"29","author":"A Solta","year":"2023","unstructured":"Solta A, Boettiger K, Kovacs I, Lang C, Megyesfalvi Z, Ferk F, et al. Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair. Clin Cancer Res. 2023;29:4644\u201359.","journal-title":"Clin Cancer Res"},{"key":"3177_CR35","doi-asserted-by":"crossref","unstructured":"Sogorina EM, Kim ER, Sorokin AV, Lyabin DN, Ovchinnikov LP, Mordovkina DA, et al. YB-1 phosphorylation at serine 209 inhibits its nuclear translocation. Int J Mol Sci. 2021;23:428.","DOI":"10.3390\/ijms23010428"},{"key":"3177_CR36","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2202","volume":"10","author":"AL Stratford","year":"2008","unstructured":"Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008;10:R99.","journal-title":"Breast Cancer Res"},{"key":"3177_CR37","doi-asserted-by":"publisher","unstructured":"Lettau K, Forchhammer S, Fehrenbacher B, Mahmutovic L, Scharpf M, Blumenstock G, et al. The subcellular distribution of phosphorylated Y-box-binding protein-1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features. Mol Oncol. 2025. https:\/\/doi.org\/10.1002\/1878-0261.70060","DOI":"10.1002\/1878-0261.70060"},{"key":"3177_CR38","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2845","volume":"13","author":"M Toulany","year":"2011","unstructured":"Toulany M, Schickfluss TA, Eicheler W, Kehlbach R, Schittek B, Rodemann HP. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011;13:R28.","journal-title":"Breast Cancer Res"},{"key":"3177_CR39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"3177_CR40","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","volume":"12","author":"LA Marek","year":"2014","unstructured":"Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK, Boehm D, et al. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res. 2014;12:1460\u20139.","journal-title":"Mol Cancer Res"},{"key":"3177_CR41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40164-023-00462-7","volume":"12","author":"C Quan","year":"2023","unstructured":"Quan C, Wu Z, Xiong J, Li M, Fu Y, Su J, et al. Upregulated PARP1 confers breast cancer resistance to CDK4\/6 inhibitors via YB-1 phosphorylation. Exp Hematol Oncol. 2023;12:100.","journal-title":"Exp Hematol Oncol"},{"key":"3177_CR42","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1038\/onc.2010.365","volume":"29","author":"J Dhillon","year":"2010","unstructured":"Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010;29:6294\u2013300.","journal-title":"Oncogene"},{"key":"3177_CR43","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1535-7163.MCT-19-0690","volume":"19","author":"T Shibata","year":"2020","unstructured":"Shibata T, Watari K, Kawahara A, Sudo T, Hattori S, Murakami Y, et al. Targeting phosphorylation of Y-box-binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance. Mol Cancer Ther. 2020;19:882\u201394.","journal-title":"Mol Cancer Ther"},{"key":"3177_CR44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cells9010104","volume":"9","author":"DA Kretov","year":"2019","unstructured":"Kretov DA, Mordovkina DA, Eliseeva IA, Lyabin DN, Polyakov DN, Joshi V, et al. Inhibition of transcription induces phosphorylation of YB-1 at Ser102 and its accumulation in the nucleus. Cells. 2019;9:104.","journal-title":"Cells"},{"key":"3177_CR45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/cancers12020315","volume":"12","author":"S Mehta","year":"2020","unstructured":"Mehta S, McKinney C, Algie M, Verma CS, Kannan S, Harfoot R, et al. Dephosphorylation of YB-1 is required for nuclear localisation during G(2) phase of the cell cycle. Cancers. 2020;12:315.","journal-title":"Cancers"},{"key":"3177_CR46","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0768-1","volume":"14","author":"N Poomakkoth","year":"2016","unstructured":"Poomakkoth N, Issa A, Abdulrahman N, Abdelaziz SG, Mraiche F. p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer. J Transl Med. 2016;14:14.","journal-title":"J Transl Med"},{"key":"3177_CR47","doi-asserted-by":"crossref","unstructured":"Titova E, Shagieva G, Dugina V, Kopnin P. The role of aurora B kinase in normal and cancer cells. Biochemistry. 2023;88:2054\u201362.","DOI":"10.1134\/S0006297923120088"},{"key":"3177_CR48","doi-asserted-by":"crossref","unstructured":"Lettau K, Khozooei S, Kosnopfel C, Zips D, Schittek B, Toulany M. Targeting the Y-box binding protein-1 axis to overcome radiochemotherapy resistance in solid tumors. Int J Radiat Oncol Biol Phys. 2021;111:1072\u201387.","DOI":"10.1016\/j.ijrobp.2021.06.021"},{"key":"3177_CR49","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-11892-9","volume":"24","author":"A Yassin-Kassab","year":"2024","unstructured":"Yassin-Kassab A, Chatterjee S, Khan N, Wang N, Sandulache VC, Huang EH, et al. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer. BMC Cancer. 2024;24:233.","journal-title":"BMC Cancer"},{"key":"3177_CR50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbrc.2023.08.060","volume":"679","author":"Y Nagumo","year":"2023","unstructured":"Nagumo Y, Villareal MO, Isoda H, Usui T. RSK4 confers paclitaxel resistance to ovarian cancer cells, which is resensitized by its inhibitor BI-D1870. Biochem Biophys Res Commun. 2023;679:23\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"3177_CR51","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41375-023-01951-8","volume":"37","author":"K Weidenauer","year":"2023","unstructured":"Weidenauer K, Schmidt C, Rohde C, Pauli C, Blank MF, Heid D, et al. The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax\/azacitidine in acute myeloid leukemia. Leukemia. 2023;37:1611\u201325.","journal-title":"Leukemia"},{"key":"3177_CR52","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene"},{"key":"3177_CR53","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00432-002-0386-6","volume":"128","author":"H Yahata","year":"2002","unstructured":"Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol. 2002;128:621\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3177_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-017-3011-3","volume":"433","author":"H Wang","year":"2017","unstructured":"Wang H, Sun R, Chi Z, Li S, Hao L. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-kappaB signaling pathway in human neuroblastoma SH-SY5Y cells. Mol Cell Biochem. 2017;433:1\u201312.","journal-title":"Mol Cell Biochem"},{"key":"3177_CR55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopha.2016.01.037","volume":"79","author":"J Xu","year":"2016","unstructured":"Xu J, Hu Z. Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma. Biomed Pharmacother. 2016;79:17\u201322.","journal-title":"Biomed Pharmacother"},{"key":"3177_CR56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ijrobp.2020.09.005","volume":"109","author":"K Lettau","year":"2021","unstructured":"Lettau K, Zips D, Toulany M. Simultaneous targeting of RSK and AKT efficiently inhibits YB-1-mediated repair of ionizing radiation-induced DNA double-strand breaks in breast cancer cells. Int J Radiat Oncol Biol Phys. 2021;109:567\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3177_CR57","doi-asserted-by":"crossref","unstructured":"Maier E, Attenberger F, Tiwari A, Lettau K, Rebholz S, Fehrenbacher B, et al. Dual targeting of Y-box binding protein-1 and Akt inhibits proliferation and enhances the chemosensitivity of colorectal cancer cells. Cancers. 2019;11:562.","DOI":"10.3390\/cancers11040562"},{"key":"3177_CR58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1535-7163.MCT-21-1037","volume":"23","author":"K Ichikawa","year":"2024","unstructured":"Ichikawa K, Ito S, Kato E, Abe N, Machida T, Iwasaki J, et al. TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models. Mol Cancer Ther. 2024;23:174\u201386.","journal-title":"Mol Cancer Ther"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03177-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03177-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03177-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:46:11Z","timestamp":1761774371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03177-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,16]]}},"alternative-id":["3177"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03177-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Tissue specimens from PM and normal pleura were collected at the Medical University of Vienna in accordance with the Declaration of Helsinki. Tissue collection and analysis and establishment of cell cultures has been approved by the Ethics Committee of the Medical University of Vienna (EK #904\/2009) and all patients have provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}